Tony's Chocolonely bars recalled for possibly containing ‘small stones'
A chocolate manufacturer has issued a voluntary recall of certain chocolate bars sold in the U.S. and Canada, because they could contain "small stones."
Tony's Chocolonely Inc., based in Amsterdam, Netherlands and has offices in places like New York City, announced the recall on Monday, saying the chocolate bars in question were distributed to retailers in Canada and the U.S.
According to the announcement, seven lots of Tony's brand Dark Almond Sea Salt Bar (6.35 oz) and Everything Bar (6.35 oz) were being recalled "because the product may contain small stones."
The candy bars were sold in U.S. retail stores and on the company's website, www.tonyschocolonely. The notice said distribution of the recalled bars began on Feb. 7 and ended on March 24.
Fda Recalls Cheese Sold At Aldi Locations In 4 States
"Whilst the chance of any individual product being affected is low, we have decided to take this step to ensure the safety and satisfaction of Tony's Chocolonely consumers," the company said.
Read On The Fox Business App
The company added that a limited number of consumers reported that they found small stones in the product, which were not filtered during third-party almond harvesting and almond processing.
The products being recalled are identified with the following lot code, best-by date and UPC:
Tony's Chocolonely Everything Bar (180g / 6.35 oz):
4327, 22-Nov-25, 850011828564
4330, 25-Nov-25, 850011828564
4331, 26-Nov-25, 850011828564
M4331, 26-Nov-25, 850032676441
Thousands Of Pounds Of Ground Coffee Recalled Due To Mislabeling Error: Fda
Tony's Chocolonely Dark Chocolate Almond Sea Salt (180g / 6.35 oz):
163094, 2-Apr-26, 858010005641
162634, 28-Feb-26, 858010005641
M162634, 28-Feb-26, 850011828908
In Canada, Dark Almond Sea Salt, 180g products, with a lot number of 162697, and Everything bar, 180g products, with a lot number of 4332, were also recalled.
Trader Joe's Recalls Sparkling Water Bottles Over 'Laceration Hazard': 'Dispose Of Them Carefully'
Lot codes are unique identifiers assigned to a batch or quantity of products manufactured under the same conditions and used for tracking and traceability, the company said.
For the bars in question, the lot code is printed on the side of the candy bar wrapper and usually starts with the letter "L" for everyday items, and "M" for personalized items.
No other lot codes were included in the voluntary recall, and Tony's Chocolonely said the action was taken to ensure the safety of its consumers, as a precautionary measure.
Click Here To Read More On Fox Business
Consumers who possess one of the candy bars in question are encouraged to return the item to the store it was purchased from for a refund or replacement or simply dispose of the product.Original article source: Tony's Chocolonely bars recalled for possibly containing 'small stones'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Alligator Bioscience Receives FDA Endorsement of Mitazalimab Phase 3 Dose for Pancreatic Cancer
LUND, SE / / June 13, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has provided feedback supporting the selection of the 900 µg/kg dose of its CD40 agonist mitazalimab for the planned Phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC). This positive regulatory feedback confirms Alligator's dose selection and represents a key milestone in the late-stage development of mitazalimab. "We are very pleased with the FDA's timely and constructive response. This marks an important step forward as we finalize our Phase 3 program for mitazalimab in one of the most aggressive and underserved cancers. We are now in active partnering dialogues aiming to secure the right partner to take mitazalimab into Phase 3," said Søren Bregenholt, CEO of Alligator Bioscience . For further information, please contact: Søren Bregenholt, CEOE-mail: +46 (0) 46 540 82 00 The information was submitted for publication, through the agency of the contact person set out above, at 8:45 a.m. CEST on 13 June 2025. About Alligator Bioscience Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer. The Company's lead drug candidate mitazalimab is currently in preparation for Phase 3 development, and has previously presented unprecedented survival data at 24-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1. Alligator is listed on Nasdaq Stockholm (ATORX) and headquartered in Lund, Sweden. For more information, please visit . Attachments Alligator Bioscience receives FDA endorsement of mitazalimab Phase 3 dose for pancreatic cancer SOURCE: Alligator Bioscience View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Novavax's COVID-Flu Combo Shot Shows Strong Immune Response
Novavax NVAX announced encouraging results from an initial cohort of a late-stage study evaluating its experimental COVID-19-influenza combination (CIC) and stand-alone influenza vaccine candidates. Results showed that the CIC and flu vaccines generated 'robust immune responses' across three flu strains (H1N1, H3N2 and B) and the SARS-CoV-2 strain in adults aged 65 and older. Per Novavax, these responses were similar to those seen with its own approved COVID-19 vaccine, Nuvaxovid, and Sanofi's SNY influenza vaccine, Fluzone HD. Novavax emphasized that this study was not designed to demonstrate statistical significance but to provide preliminary immunogenicity data. It intends to use these findings to design another late-stage study, which could potentially support regulatory submissions, if successful. NVAX is also exploring strategic collaborations to finance further development and potential commercialization of both candidates. This is part of the company's recent strategic shift focused on expanding its pipeline and exploring partnership opportunities for the same. Shares of Novavax have underperformed the industry year to date, as seen in the chart below. Image Source: Zacks Investment Research The above announcement came just under a month after it received the long-awaited FDA approval for Nuvaxovid, albeit with a narrower label than initially expected. While the agency granted full approval to the vaccine for use in older adults aged 65 and above, it restricted the use in individuals aged 12-64 with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19. This latest approval aligns with the FDA's recently issued guidance for COVID-19 vaccine boosters. As part of this guidance, COVID vaccine makers will be required to conduct randomized, placebo-controlled clinical studies demonstrating the real-world benefit of yearly COVID vaccine boosters in individuals aged under 65 years. Starting this year, Sanofi has acquired exclusive rights to market Nuvaxovid globally, except in certain territories where Novavax maintains existing partnership agreements. This arrangement is part of a multi-billion-dollar deal signed last year, wherein Sanofi assumed commercial responsibility for the vaccine. The company is also eligible for ongoing tiered royalties on future sales of COVID-19 vaccines. Apart from Novavax, Pfizer PFE and Moderna MRNA are also developing their respective COVID/flu combination vaccines using mRNA technology. Despite the recent regulatory setback, Moderna remains ahead of its competitors with the development of its investigational COVID-19/flu vaccine candidate, mRNA-1083. Moderna had to voluntarily withdraw its FDA filing for mRNA-1083 to accommodate the agency's request for additional efficacy data on the flu component of the vaccine. Moderna intends to resubmit the filing later this year. Pfizer suffered a major setback in this space last year when it reported data from a phase III study on its investigational mRNA-based COVID-19/flu combination vaccine. The study missed one of its two primary immunogenicity objectives. Pfizer is currently evaluating adjustments to its combination vaccine program to improve immune responses against influenza B and plans to discuss the next steps with health authorities. Pfizer is developing this vaccine in collaboration with BioNTech. Novavax's deal with Sanofi also allows the latter to combine its own influenza vaccines with Nuvaxovid. Sanofi is currently testing multiple COVID-19/flu combination vaccine candidates under this arrangement. Last year, the FDA granted fast-track designation to two of Sanofi's experimental combination vaccines, both being evaluated in separate phase I/II studies. While the first combination uses the Fluzone HD vaccine with Nuvaxovid, the second pairs Novavax's COVID-19 shot with Flubok. Novavax, Inc. price | Novavax, Inc. Quote Novavax currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Sanofi (SNY) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report Moderna, Inc. (MRNA) : Free Stock Analysis Report Novavax, Inc. (NVAX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Miami Herald
9 hours ago
- Miami Herald
Augnition Labs Announces FDA Classification for Flagship Product, AugMem(TM)
NEW YORK CITY, NEW YORK / ACCESS Newswire / June 12, 2025 / Augnition Labs, a neurotechnology company developing science-driven tools to advance cognitive health, today announced that its flagship product, AugMem™, has been classified by the FDA as a Prescription Use Cognitive Assessment Aid (PTY). This significant milestone paves the way for clinical deployment to support evaluation of cognitive function and help identify changes that may indicate early cognitive decline. Grounded in more than two decades of neuroscientific research by Co-Founder and Chief Scientific Advisor, Dr. Michael Yassa, AugMem™ evaluates pattern separation - a core brain process that enables us to form distinct memories. Subtle impairments in this mechanism often precede clinical symptoms of cognitive decline by 10-15 years. "Early detection is critical. If we wait until memory loss is obvious, decline can be irreversible," said Yassa. "This FDA classification is a major step forward. It opens the door for us to deploy it in healthcare settings. Our goal is to make ultrasensitive cognitive assessment available where it's needed most-at the frontlines of care, before symptoms become disabling." In addition to this regulatory milestone, Augnition Labs also announced key leadership appointments to strengthen its path to growth and impact. Ernst Wodrada, a seasoned executive in the medical technology industry, has joined Augnition as President. Ernst brings leadership experience from global healthcare organizations, including Philips, where he led efforts in imaging, image-guided therapy, and healthcare innovation. "I am honored and excited to join Augnition Labs, working alongside this fantastic team to forge meaningful partnerships with clinical experts and investors," Wodrada said. "Cognitive decline presents profound challenges, and together, we are committed to pioneering solutions that empower individuals and caregivers." Ali Kennedy Scott, a member of Augnition's founding team, will step into the role of Managing Director. A former Bain & Company consultant, Kennedy Scott brings expertise in growth strategy, organizational effectiveness, and customer insight, with experience spanning healthcare, consumer products, and private equity-backed ventures. The company also welcomes Dr. Chris Bun as Head of Technology. With a background in AI, machine learning, and healthcare technology, Dr. Bun will lead development of Augnition's core platform, applying advanced AI and user-centered design to cognitive assessment tools. "We are deeply proud of the momentum behind AugMem™ and of this team that's come together to shape the future of cognitive assessments," said Kennedy Scott. "This FDA classification is a foundational step in our mission to equip patients, caregivers, and healthcare providers with tools that enhance clarity, agency, and hope." Augnition collaborates with leading academic institutions, industry researchers, clinicians, and healthcare systems to create accessible, evidence-based tools for cognitive health. About Augnition LabsAugnition Labs develops science-driven tools to advance cognitive health. The company was founded on the scientific work of Dr. Michael Yassa, a globally recognized expert in the neurobiology of memory and Alzheimer's Disease. With a focus on clinical utility, human-centered design, and early intervention, Augnition empowers patients, researchers, and clinicians to better understand the brain and respond to change. SOURCE: Augnition Labs press release
